Chase Knickerbocker

David Amsellem

Jason Dorr

Leland Gershell

Mazahir Alimohamed

Oren Livnat

Alex Riesemann

Christian Clark

Glen Santangelo

- Beta Bionics reported **net sales of $27.3 million** for the third quarter of 2025, representing a **63% increase** compared to the third quarter of 2024.  **[1867096_0884104c06084db2818845243efbc5d7_0]** 
- The company's **net loss** for Q3 2025 was **$14.2 million**.  **[1867096_0884104c06084db2818845243efbc5d7_0]** 
- As of September 30, 2025, Beta Bionics had **$274.0 million** in cash, cash equivalents, short-term investments, and long-term investments.  **[1867096_0884104c06084db2818845243efbc5d7_0]** 
- Beta Bionics **raised its full-year 2025 total revenue guidance** to **greater than $96.5 million** (previously $88 million to $93 million) and its **estimated gross margin** to **54% to 55%** (previously 52% to 55%).  **[1867096_0884104c06084db2818845243efbc5d7_1]**

Beta Bionics Reports Q3 2025 Financial Results and Raises Full Year Guidance

Xeris Biopharma Holdings (XERS)